join mochi semaglutide I joined again : r/JoinMochiHealth FAQ | Mochi Health
Description
Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes
About 6% of people chose to stop taking the drug before the trial ended because of side effects
Additionally, the authors also conducted a snowball search to find other articles
In fact, cardiovascular disease is the leading cause of death in MASLD patients 3,6
In large clinical trials, tirzepatide demonstrated significant total body weight loss over time
